AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06003465
Drug: LY3437943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06431685
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed at a dose of 500 mg/m\^2, intravenous infusion, once per three weeks, 4 cycles in total
Trial: NCT05320107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl
Trial: NCT04875026
Drug: 5-fluorouracil 4% (Tolak)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of Tolak once daily in the evening for 4 weeks
Trial: NCT05523141
Drug: ASC10
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo for 5.5 days, in an double-blind manner~Part 2:~Two single oral doses of ASC10 will be administered to participants, in an open-label manner
Trial: NCT05523141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo, in an double-blind manner
Trial: NCT01825083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 % normal saline group receives same volume as the ketamine dose
Trial: NCT05735379
Drug: Deprescribing anticholinergic and sedative mediications
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5
Trial: NCT04989972
Drug: PSIL428
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of psilocybin
Trial: NCT04989972
Drug: PSIL428
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg psilocybin
Trial: NCT05823714
Drug: VEN+AZA+Modified BUCY
RxNorm normalized name: Apis mellifera ven protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days.
Trial: NCT05556564
Drug: observational study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No intervention, observational study
Trial: NCT05610800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.
Trial: NCT05008809
Drug: CAPOX
RxNorm normalized name: Capecitabine and Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine: 1000 mg/m², oral 1-0-1 on d1-14 Oxaliplatin: 130 mg/m², 3h IV infusion on d1 Cycles are repeated on day 22. A total of up to 8 cycles isadministered.
Trial: NCT04932746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol
Trial: NCT01223053
Drug: Ketoprofen 10% cream
RxNorm normalized name: KETOPROFEN 10% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days. Safety follow up on day 14.
Trial: NCT01223053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
Trial: NCT05866367
Drug: Low dose Regular Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin administered intranasally at either 40 IU
Trial: NCT05866367
Drug: High dose Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin administered intranasally at either 80 IU
Trial: NCT06245122
Drug: CS23546
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally.
Trial: NCT04859660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
Trial: NCT05347849
Drug: BPL-003
RxNorm normalized name: BANDAGE KIT,COMPRESSION LYMPHEDEMA#BPLEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of BPL-003 will be administered intranasally
Trial: NCT04416737
Drug: Ultra-rapid insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.
Trial: NCT04765995
Drug: HZBio1 3mg / kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
Trial: NCT04765995
Drug: HZBio1 6mg / kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
Trial: NCT04765995
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered intramuscularly.
Trial: NCT05536102
Drug: PLD
RxNorm normalized name: PLD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/m2, day 1, q3w
Trial: NCT05536102
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2, days 1-14, q3w
Trial: NCT05842330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be strictly identical (same packaging, size no. 2 and color according to dosage, with no label).~Procedure for adjustment of dosage will be the same as in the Concerta arm.
Trial: NCT00517894
Drug: CEOP/IMVP-Dexa chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28
Trial: NCT05047731
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication will be continually reduced provided an upper systolic threshold of 145 mmHg is not exceeded
Trial: NCT06250634
Drug: Vonoprazan + amoxicillin + clarithromycin
RxNorm normalized name: clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg twice daily of vonoprazan fumarate tablets, 1000 mg twice daily of amoxicillin capsules and 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical)
Trial: NCT06260267
Drug: Placebo suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension
Trial: NCT06260267
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT00041665
Drug: Recombinant Human Keratinocyte Growth Factor
RxNorm normalized name: Recombinant human keratinocyte growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03540355
Drug: Cipros 20 association
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once a day
Trial: NCT04750902
Drug: 1.5% Arginine Dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
Trial: NCT04750902
Drug: 4.0% Arginine Dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
Trial: NCT04750902
Drug: 8.0% Arginine Dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
Trial: NCT04981093
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2ml of normal saline was injected intravenously after induction of anesthesia
Trial: NCT05046522
Drug: Palmitoylethanolamide sold as Levagen +
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.
Trial: NCT06262061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill orally BID x 14 days
Trial: NCT06649448
Drug: TP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The chemotherapy regimen options include:~TP regimen: Cisplatin 60-80 mg/m² administered via intravenous drip on Day 1 + Taxane: Paclitaxel 175 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, with a treatment cycle of every 3 weeks (Q3W).
Trial: NCT04789928
Drug: Gentamicins-EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients included in this study will receive daily injection (up to 10 days) of genta-EDTA-Na2 lock associated with systemic antibiotics.
Trial: NCT00888680
Drug: BGC20-1531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGC20-1531 administered orally
Trial: NCT00888680
Drug: Lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally
Trial: NCT05073172
Drug: Topical Hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically
Trial: NCT03438526
Drug: Melatonin (Circadin ®)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg of oral melatonin at 8 p.m. for the length of the duration of the hypoactive delirium
Trial: NCT03438526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose monohydrate, cellulose powder, magnesium stearate (Ph. Eur.), mocrocristalline cellulose
Trial: NCT06319846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial infusion of saline placebo for 30 minutes within 24 hours of symptom onset, followed by a continuous infusion of placebo for 48 hours.
Trial: NCT03817034
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given a rectus sheath block containing dexmedetomidine, ropivacaine, and ketorolac
Trial: NCT06241183
Drug: Oral Maalox/ Mylanta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive 30 ml Maalox/ Mylanta.
Trial: NCT05155995
Drug: HCP2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period.
Trial: NCT05155995
Drug: RLD2007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period.
Trial: NCT05155995
Drug: RLD2102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period.
Trial: NCT04500665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06305910
Drug: Treatment with CD200AR-L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with CD200AR-L (up to 3 dose levels of CD200AR-L with a Dose Level -1 in the event of toxicity) with fixed doses of GBM6-AD vaccine. Each patient will also be given topical imiquimod and a single dose of 300cGy re-irradiation.
Trial: NCT05651802
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
Trial: NCT05716854
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive the Clarithromycin intervention orally according to the following schedule:~Day 1: 1 Clarithromycin 500 mg immediate release (IR) tablet twice (Clarithromycin 500 mg BID).~Day 2: 2 Clarithromycin 500 mg immediate release (IR) tablets twice (Clarithromycin 1000 mg BID).~Day 3: 2 Clarithromycin 500 mg immediate release (IR) tablets once (Clarithromycin 1000 mg QD).
Trial: NCT00002004
Drug: CD4 Antigens
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05640245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: randomized treatment; parallel-group
Trial: NCT04742660
Drug: Ammonium Glycyrrhizinate
RxNorm normalized name: AMMONIUM GLYCYRRHIZINATE TRIHYDRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In control group, we assess the incidence and severity of PONV when participants are aministered ramosetron and placebo. In intervention group, the outcomes are assessed as a result of administration of ramosetron and glycyrrhizin.
Trial: NCT05400395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral intake(BID) for 24 weeks
Trial: NCT05674877
Drug: Opioid-based group (OB) (placebo/saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the opioid-based group will receive placebo boluses and infusions of saline.
Trial: NCT05674877
Drug: Opioid sparing group (OS) (dexmedetomidine (PRECEDEX™ dexmedetomidine hydrochloride - Pfizer) and ketamine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the Opioid Sparing group will receive a dexmedetomidine (PRECEDEX™ dexmedetomidine hydrochloride - Pfizer) and ketamine.
Trial: NCT05278338
Drug: JMT103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
Trial: NCT05278338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
Trial: NCT06505551
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: for 3 consecutive days
Trial: NCT04683939
Drug: BNT141
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV)
Trial: NCT05709444
Drug: RAAS inhibition therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.
Trial: NCT04936698
Drug: PTU 50 MG Oral Tablet
RxNorm normalized name: PTU 50 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to treat if the patient has hyperthyroidism
Trial: NCT06598371
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV
Trial: NCT06598371
Drug: KSQ-004EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT04327661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT06381154
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06381154
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06381154
Drug: Photodynamic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo intratumoral photoradiation
Trial: NCT01874314
Drug: SQ109
RxNorm normalized name: SQ109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg or 450mg of SQ109 administered orally, once daily for 7 days.
Trial: NCT04466215
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six placebo tablets taken orally once daily for two weeks
Trial: NCT03164447
Drug: Optimized background therapy (OBT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.
Trial: NCT06487598
Drug: inj insulin to one group
RxNorm normalized name: Gel-One Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One group- only inj insulin for 3 months.
Trial: NCT06487598
Drug: Inj Insulin with Tab Nisha-Amalaki 500 mg twice a day
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: second group- Inj Insulin with Tab Nisha-Dhatri 500 mg twice a day
Trial: NCT06625073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
Trial: NCT06626113
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ascorbic acid
Trial: NCT06155383
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2, Bid orally, D1-14, every 3 weeks
Trial: NCT04737109
Drug: Androgen Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT per institutional standards
Trial: NCT05384665
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: REMIFENTANIL, 5 µg/cc, solution for injection, 0.5 µg/kg, parenteral (intravenous) route, injection delay of 30 seconds, once only
Trial: NCT05384665
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SUFENTANIL, 5 µg/cc, solution for injection, 0.2 µg/kg, parenteral (intravenous) route, bolus over 5 seconds, once
Trial: NCT05384665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO contains 0.9% NaCl, parenteral (intravenous), bolus, one-time
Trial: NCT05646394
Drug: Vitamin K antagonist standard intensity
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 2.0-3.0
Trial: NCT05646394
Drug: Vitamin K antagonist high intensity
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 3.0-4.0
Trial: NCT05483894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 12 weeks and than Atorvastatin(Lipinon Tab. 10mg) for 12 weeks for control group
Trial: NCT06620523
Drug: CoQ10 1200 mg orally with Glutathione 1000 mg orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the intervention to assess efficacy of CoQ10 and Glutathione in prevention of cardiac surgery associated acute kidney injury
Trial: NCT06620523
Drug: Group B: Placebo CoQ10 orally and Placebo Glutathione orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.
Trial: NCT04916119
Drug: IBI323
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K
Trial: NCT05905068
Drug: RN0191 INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a sterile solution in each bottle for subcutaneous (SC) injection
Trial: NCT05044325
Drug: GSK3884464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3884464 will be administered
Trial: NCT05044325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GSK3884464 will be administered.
Trial: NCT04789174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05008393
Drug: PJS-539 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive PJS-539 dose 1 daily for 10 days.
Trial: NCT05008393
Drug: PJS-539 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive PJS-539 Dose 2 daily for 10 days.
Trial: NCT05008393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo daily for 10 days.
Trial: NCT05596006
Drug: ASIMOMMY®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASIMOMMY 500 mg
Trial: NCT05596006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of placebo 500mg.
Trial: NCT05043701
Drug: Personalized drug combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A personalized drug combination will be prescribed to each patient based on the functional drug screen
Trial: NCT05600062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule